Advertisement

Alzheimer

  • Jerzy Leszek
  • Andrzej Kiejna
  • Ulrich Michael Hemmeter
  • Ulrich Kropiunigg
Chapter

Abstract

On November 3rd 1906, Aloys Alzheimer presented to the Meeting of the Psychiatrists the neuropathological and clinical features of Auguste D., who had died of dementing illness at the age of 55. The disease was given its eponym by his senior colleague E. Kraepelin. The description initiated the slow separation between Alzheimer’s disease (AD) and other causes of presenile dementia (Hardy 2006).

Keywords

Cholinesterase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bidzan L, Turczynski J (2005) Environment and cognitive functions in a population 60 years and older (Prevalence of dementia in a rural population). Psychiatr Pol 39; 1211–1218PubMedGoogle Scholar
  2. Cacabelos R (2007) Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Methods Find Exp Clin Pharmacol 29: Suppl AGoogle Scholar
  3. Campbell DE, Lynn J., Louis TA, Shugarman LR (2004) Medicine program expenditures associated with hospice use. Ann Intern Med 140: 269–277PubMedGoogle Scholar
  4. Clegg A, Bryant J, Nicholson T (2001) Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: A rapid and systematic review. Health Technol Assess 5: 1–137Google Scholar
  5. Das SK, Biswas A, Roy T et al. (2006) A random sample survey for prevalence of major neurological disorders in Calcutta. Indian J Med Res 124: 163–172Google Scholar
  6. Dong MJ, Peng B, Lin XT et al. (2007) The prevalence of dementia in the People’s Republic of China: a systematic analysis of 1980–2004 studies. Age Ageing 36: 619–624PubMedCrossRefGoogle Scholar
  7. Ferri CL, Prince M et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112–2117PubMedCrossRefGoogle Scholar
  8. Ferri CP, Prince M, Brayne C et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112–2117PubMedCrossRefGoogle Scholar
  9. Gabryelewicz T (1999) The prevalence of dementia in the population of the Warsaw district of Mokotow from 65 to 84 years of age. Psychiatr Pol 33: 353–366PubMedGoogle Scholar
  10. Giacobini E (2006) Cholinoesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer’s disease and related disorders. In: Giacobini E, Pepeu G (eds) The brain cholonergic system in health and disease. Informal Healthcare, Oxon, pp 235–264Google Scholar
  11. Glaser A (2008) Merz Pharmaceuticals, Frankfurt. http://www. merz.de/presse/pressemappen_gesundheit/alzheimer/verlauf/Google Scholar
  12. Hardy J (2007) A hundred years of Alzheimer’s disease research. NEURON 52:3–13CrossRefGoogle Scholar
  13. Hofman A et al. (1991) The prevalence of dementia In Europe: a collaborative study of 1980–1990 findings. Int J Epidemiol 20: 736–748PubMedCrossRefGoogle Scholar
  14. Jacob KS, Kumar PS, Gayathri K et al. (2007) The diagnosis of dementia in the community. Int Psychogeriatr 19: 669–678PubMedCrossRefGoogle Scholar
  15. Loveman E, Green C, Kirby J (2006) The clinical and costeffectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess 10: 1–176Google Scholar
  16. Molero AE, Pino-Ramirez G., Maestre GE (2007) High prevalence of dementia in Caribbean population. Neuroepidemiology 29: 107–112PubMedCrossRefGoogle Scholar
  17. Ogeng’o JA, Cohen DL, Sayi JG (1996) Cerebral amyloid beta protein deposits and other Alzheimer lesions in nondemented elderly east Africans. Brain Pathol 6: 101–107CrossRefGoogle Scholar
  18. Prince M, Acosta D, Chiu H, Scazufca M, Varghese M (2003) Dementia diagnosis in developing countries: a cross-cultural validation study. Lancet 361: 909–917PubMedCrossRefGoogle Scholar
  19. Prince M, Ferri CP, Acosta D (2007) The protocols for the 10/66 Dementia Research Group population-based research programme. BMC Public Health 2: 165CrossRefGoogle Scholar
  20. Prince MJ (1997) The need for research on dementia in developing countries. Trop Med Int Health 2: 993–1000PubMedGoogle Scholar
  21. Raicher I, Shimizu MM, Takahashi DY et al. (2008) Alzheimer’s disease diagnosis disclosure in Brazil: a survey of specialized physicians’ current practice and attitudes. Int Psychogeriatr 20: 471–481PubMedCrossRefGoogle Scholar
  22. Rodriguez JJL, Ferri CP, Acosta D et al. (2008) The prevalence of dementia in Latin America, India and China. A 10/66 Dementia Research Group population-based survey. Lancet 372: 464–474PubMedCrossRefGoogle Scholar
  23. Rossa G (1997) The prevalence of Alzheimer’s type dementia and vascular dementia in the district of Swieboclzin. Psychiatr Pol 31: 121–134PubMedGoogle Scholar
  24. Suh GH, Shah A (2001) A review of the epidemiological transition in dementia-cross-national comparisons of the indices related to Alzheimer’s disease and vascular dementia. Acta Psychiatr Scand 104: 4–11PubMedCrossRefGoogle Scholar
  25. Tschanz JT (2006) Conversion to dementia from mild cognitive disorder. Neurology 67: 2CrossRefGoogle Scholar
  26. Waldemar G, Phung KT, Burns A et al. (2007) Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry 22: 47–54PubMedCrossRefGoogle Scholar
  27. Wender M, Mularczyk J, Modestowicz R (1990) Epidemiology of Alzheimer’s disease in the selected region of Wielkopolska (town and commune Steszew). Przegl Epidemiol 44: 215–221PubMedGoogle Scholar
  28. WHO (2002) Active ageing: a policy framework, 2002 health report. World Health Organization, GenevaGoogle Scholar
  29. Wimo A, Jonsson L, Winbaad B (2006) An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21: 175–181PubMedCrossRefGoogle Scholar
  30. Zhang ZX, Zahner GE, Roman GC, et al. (2006) Socio-demographic variation of dementia subtypes in china: methodology and results of prevalence study in Beijing, Chengdu, Shanghai, and Xian. Neuroepidemiology 27: 177–187PubMedCrossRefGoogle Scholar

References

  1. Alf C, Bancher C, Benke T, Berek K et al. (2006) Konsensusstatement “Demenz” der Österreichischen Alzheimer Gesellschaft, update 2006. Neuropsychiatrie 2006; 20: 221–221Google Scholar
  2. Areosa SA, Sherriff F, McShane R (2005) Memantine for dementia. Cochrane Database Syst Rev 3: CD003154PubMedGoogle Scholar
  3. Bassuk SS, Glass TA, Berkman LF (1999) Social disengagement and incident cognitive dedine in community-dwelling elderly persons. Ann Intern Med 131: 165–173PubMedGoogle Scholar
  4. Bowie P, Branton T, Holmes J (1999) Should the Mini Mental State Examination be used to monitor dementia treatments? Lancet 354: 1527–1528PubMedCrossRefGoogle Scholar
  5. Campbell Ss, Dawson D, Anderson MW (1993) Alleviation of sleep maintenance insomnia with timed exposure to bright light. J Am Geriatr Soc 8: 829–836Google Scholar
  6. Cardinali DP, Brusco LI, Liberczuk C, Furio AM (2002) The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett Suppl 1: 20–23Google Scholar
  7. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N (2002) Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease. A systematic review. Int J Technol Assess Health Care 18: 497–507PubMedCrossRefGoogle Scholar
  8. Colcombe SJ, Erickson KI, Raz N, Webb AG, Cohen NJ, McAuley E, Kramer AF (2003) Aerobic fitness reduces brain tissue loss in aging humans. J Gerontol A Biol Sci Med Sci 58: 176–180PubMedGoogle Scholar
  9. Colcombe SJ, Kramer AF, Erickson KI et al. (2004) Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci USA 101: 3316–3321PubMedCrossRefGoogle Scholar
  10. Cummings JL (2004) Drug therapy: Alzheimer’s Disease. N Engl J Med 351: 56–67PubMedCrossRefGoogle Scholar
  11. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I (2006) Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J clin Pract 60: 110–118PubMedCrossRefGoogle Scholar
  12. Doody RS, Stevens JC, Beck C et al. (2001) Practice Parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154–1166PubMedGoogle Scholar
  13. Erkinjuntti T, Román G, Gauthier S, Feldman H, Rockwood K (2004) Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35: 1010–1017PubMedCrossRefGoogle Scholar
  14. Evans JG, Wilcock G, Birks J (2004) Evidence-based pharmacotherapy of Alzheimer’s disease. Int J Neuropsychopharmacol 7: 351–769PubMedCrossRefGoogle Scholar
  15. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavorial Disturbances. www.fda. gov/cder/drug/advisory/antipsychotics.htm.Google Scholar
  16. Fratiglioni L, Wang HX, Ericsson K, Maytan M, Winblad B (2000) Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet 355: 1315–1319PubMedCrossRefGoogle Scholar
  17. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63: 1402–1408PubMedCrossRefGoogle Scholar
  18. Gage FH (2002) Neurogenesis in the adult brain. J Neurosci 22: 612–613PubMedGoogle Scholar
  19. Gaines JM, Miller KJ, Parrish JM et al. (2007) Effects of a healthy aging intervention program on older adults: The Memory Fitness Study. Poster presented at: National Gerontological Nursing Association’s 22nd Annual Conference; October 18–21, 2007; Orlando, FLGoogle Scholar
  20. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102 1095–1104PubMedCrossRefGoogle Scholar
  21. Glass TA, De Leon CF, Bassuk SS, Berkman LF (2006) Social engagement and depressive symptoms in late life: longitudinal findings. J Aging Health 18: 604–628PubMedCrossRefGoogle Scholar
  22. Graff MJ, Adang EM, Vernooij-Dassen MJ, Dekker J, Jönsson L, Thijssen M, Hoefnagels WH, Rikkert MG (2006) Community based occupational therapy for patients with dementia and their care givers: randomized controlled trial. BMJ 333: 1196–1201PubMedCrossRefGoogle Scholar
  23. Graff MJ, Vernooij-Dassen MJ, Thijssen M, Dekker J, Hoefnagels WH, Olderikkert MG (2007) Effects of community occupational therapy on quality of life, mood, and health status in dementia patients and their caregivers: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 62: 1002–1009PubMedGoogle Scholar
  24. Hathcock JN (1997) Vitamins and minerals: Efficacy and safety. Am J Clin Nutr 66: 427–437PubMedGoogle Scholar
  25. Hemmeter UM, Thum A, Krieg JC (2007) Altersinsomnie (Insomnia in the elderly), Somnologie 11: 84–98CrossRefGoogle Scholar
  26. Herrmann N, Gill SS, Bell CM, Anderson Gm, Bronskill SE, Shulman KI, Fischer HD, Sykora K, Shi HS, Rochon PA (2007) A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 55: 1517–1523PubMedCrossRefGoogle Scholar
  27. Hills R, Gray R, Stowe R et al. (2002) Drop-out bias undermines findings of improved functionality with cholinesterase inhibitors. Neurobiol Aging 23 (Suppl 1): S89Google Scholar
  28. Hogan DB, Bailey P, Black S et al. (2008) Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 179: 1019–1026PubMedGoogle Scholar
  29. Huell M, Voigt-Radloff S (2008) Nichtpharmakologische Behandlungsmethoden bei Demenzen. Nervenarzt 79 (Suppl 3): 159–164CrossRefGoogle Scholar
  30. Kahn RL, Rowe JW (1998) Successful aging. Pantheon, New YorkGoogle Scholar
  31. Relkin NR (2008) Currents state of immunotherapy for Alzheimer’s disease. CNS Spectr 13 (Suppl 16): 39–41PubMedGoogle Scholar
  32. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000) Validation of the NPI-Q a brief clinical form of the Neuropsychiatric Inventory. J Neropsychiatry Clin Neurosci 12: 233–239Google Scholar
  33. Lebert F (2003) Serotonin reuptake inhibitors in depression of Alzheimer’s disease and other dementias. Presse Med 32: 1181–1186PubMedGoogle Scholar
  34. Man SC, Durairajan SS, Kum WF, Lu JH, Huang JD, Cheng CF, Chung V, Xu M, Li M (2008) Systematic review on the efficacy and safety of herbal medicines for Alzheimer’s disease. J Alzheimers Dis 14: 209–223PubMedGoogle Scholar
  35. Gail A (2006) Mountain Self-management for people with early dementia, An exploration of concepts and supporting evidence. Dementia 5: 429–446CrossRefGoogle Scholar
  36. McDaniel MA, Maier Sf, Einstein GO (2003) Brain-specific nutrients: a memory cure? Nutrition 19: 957–975PubMedCrossRefGoogle Scholar
  37. Miller LJ (2007) The use of cognitive enhancers in behavioral disturbances of Alzheimer’s disease. Consult Pharm 22: 754–762PubMedGoogle Scholar
  38. Möller HJ (1993) Therapy of dementing diseases: value of calcium antagonists. Fortschr Med 111: 437–440PubMedGoogle Scholar
  39. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH (2006) Curry consumption and cognitive function in the elderly. Am J Epidemiol 164: 898–906PubMedCrossRefGoogle Scholar
  40. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5: 83–89PubMedCrossRefGoogle Scholar
  41. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379–397PubMedGoogle Scholar
  42. Rocamora R, Thum A, Giesler M, Haag A, Becker A, Dodel R, Penzel T, Krieg J, Hemmeter U (2005) Schlafstörungen bei degenerativen Demenzen. Somnologie 9: 139–147CrossRefGoogle Scholar
  43. Roth T, Stubbs C, Walsh JK (2005) Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28: 303–307PubMedGoogle Scholar
  44. Seltzer B (2007) Is long-term treatment of Alzheimer’s disease with cholinesterase inhibitor therapy justified? Drugs Aging 24: 881–890PubMedCrossRefGoogle Scholar
  45. Small GW, Silverman DH, Siddarth P et al. (2006) Effects of a 14-day healthy longevity lifestyle program on cognition and brain function. Am J Geriatr Psychiatry 14: 538–545PubMedCrossRefGoogle Scholar
  46. Small GW, Siddarth P, Burggren AC et al. (2009) Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry 66: 81–87PubMedCrossRefGoogle Scholar
  47. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group (2004a) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317–324PubMedCrossRefGoogle Scholar
  48. Tariot PN, Profenno LA, Ismail MS (2004b) Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 65 (Suppl 11): 11–15PubMedGoogle Scholar
  49. Unnebrink K, Windeler J (2001) Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 20: 3931–3946PubMedCrossRefGoogle Scholar
  50. Werheide K, Thöne-Otto AIT (2006) Kognitives Training bei Alzheimer Demenz. Nervenarzt 77: 549–557CrossRefGoogle Scholar
  51. Wiegand MH (2003) Drug treatment of sleep disorders in the elderly. Internist (Berl) 44: 1187–1192CrossRefGoogle Scholar
  52. Winblad B (2005) Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11: 169–182PubMedGoogle Scholar

References

  1. Adams T (1996) Kitwood’s approach to dementia and dementia care: a critical but appreciative review. J Adv Nurs 23: 948–953PubMedCrossRefGoogle Scholar
  2. Adler A (1972) Über den nervösen Charakter. Fischer, Frankfurt am MainGoogle Scholar
  3. Ballenger JF (2006) Progress in the history of Alzheimer’s disease: The importance of context. J Alzheimer’s Dis 9: 5–13Google Scholar
  4. Bauer J (1997) Möglichkeiten einer psychotherapeutischen Behandlung bei Alzheimer-Patienten im Frühstadium der Erkrankung. Nervenarzt 68: 421–424PubMedCrossRefGoogle Scholar
  5. Bauer J, Bauer H, Teising M (1994) Psychosomatische Aspekte der Alzheimer-Demenz (pp. 47–61). In: Hirsch R (Ed.) Psychotherapie bei Demenzen. Steinkopff, DarmstadtGoogle Scholar
  6. Bauer J, Qualmann J, Bauer H (1994) Psychosomatische Aspekte bei der Alzheimer Demenz und bei vaskulären Demenzformen (pp. 214–228). In: Heuf G, Kruse A, Nehen H-G, Radebold H (Eds.) Interdisziplinäre Gerontopsychosomatik. MMV Medizin Verlag, ViewegGoogle Scholar
  7. Bauer J, Stadtmuller G, Qualmann J, Bauer H (1995) Premorbid psychological processes in patients with Alzheimer’s disease and in patients with vascular dementia. Z Gerontol Geriatr 28: 179–189PubMedGoogle Scholar
  8. Bayer-Feldmann C, Greifenhagen A (1995) Group work with relatives of Alzheimer patients — a systemic approach. Psychother Psychosom Med Psychol 45: 1–7PubMedGoogle Scholar
  9. Carneiro P, Crawford C, Goodman A (2007) The impact of early cognitive and non-cognitive skills on later outcomes. Centre for the Economics of Education London School of Economics, LondonGoogle Scholar
  10. Carneiro P, Meghir C, Parey M (2007) Maternal education, home environments and the development of children and adolescents. IZA Institute for the Study of Labor, BonnGoogle Scholar
  11. Damasio AR (2003) Der Spinoza-Effekt: Wie Gefühle unser Leben bestimmen. List, MünchenGoogle Scholar
  12. Devanand DP, Sano M, Tang MX, Taylor S, Gurland BJ, Wilder D, Stern Y, Mayeux R (1996) Depressed mood and the incidence of Alzheimer’s disease in the elderly living in the community. Arch Gen Psychiatry 53: 175–182PubMedGoogle Scholar
  13. Eisenberg L (1999) Does social medicine still matter in an era of molecular medicine? J Urban Health 76: 164–175PubMedCrossRefGoogle Scholar
  14. Erikson HE (1981) The life cycle completed. Norton, New YorkGoogle Scholar
  15. Erlich HS, Blatt SJ (1985) Narcissism and object love. The metapsychology of experience. Psychoanal Study Child 40: 57–79PubMedGoogle Scholar
  16. Forsythe E (1990) Alzheimer’s Disease. The long bereavement. Faber and Faber, LondonGoogle Scholar
  17. Gidley I, Shears R (1988) Alzheimers. What it is how to cope. Unwin, London Sydney WellingtonGoogle Scholar
  18. Hanson BG (1989) Definitional deficit: a model of senile dementia in context. Fam Process 28: 281–289PubMedCrossRefGoogle Scholar
  19. Hanson BG (1991) Parts, players, and »patientin«: The social construction of senile dementia. Family Systems Medicine 9: 267–274CrossRefGoogle Scholar
  20. Havighurst RJ (1953) Developmental tasks and education. David McKay, New YorkGoogle Scholar
  21. Hodges JR (2006) Alzheimer’s centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain 129: 2811–2822PubMedCrossRefGoogle Scholar
  22. Hoffmann S (2008, Nov.) Meine Mutter, wie ein Kind (pp. 48–53). Chrismon, Hansisches Druck-und Verlagshaus, Frankfurt am MainGoogle Scholar
  23. Huether G, Doering S, Rüger U, Rüther E, Schüssler G (1996) Psychische Belastungen und neuronale Plastizität. Z Psychosom Med 42: 107–127Google Scholar
  24. Keady J, Ashcroft-Simpson S, Halligan K, Williams S (2007) Admiral nursing and the family care of a parent with dementia: using autobiographical narrative as grounding for negotiated clinical practice and decision-making. Scand J Caring Sci 21: 345–353PubMedCrossRefGoogle Scholar
  25. Kitwood T (1987a) Dementia and its pathology: in brain, mind or society? Free Associations 8: 81–93Google Scholar
  26. Kitwood T (1987b) Explaining senile dementia. Free Associations 10: 117–140Google Scholar
  27. Kitwood T (1990) Understanding senile dementia — a psychobiographical approach. Free Associations 19: 60–76Google Scholar
  28. Kitwood T, Bredin K (1992) Towards a theory of dementia care: personhood and well-being. Ageing Soc 12: 269–287PubMedCrossRefGoogle Scholar
  29. Kokmen E, Beard CM, Chandra V, Offord K-P, Schoenberg BS, Ballard DJ (1991) Clinical risk factors for Alzheimer’s disease: a population-based care-control study. Neurology 41: 1393–1397PubMedGoogle Scholar
  30. Kroplunigg U (1989) Kindheit und Erziehung bei psychosomatisch Kranken. Psychother Psychosom Med Psychol 39: 168–172Google Scholar
  31. Kropiunigg U (1999a) Alzheimer’s Disease as a result of ≫wrong≪ compensation. J Indiv Psychol 55: 395–409Google Scholar
  32. Kropiunigg U (1999b) Kompensation und ephemer-fragiles Selbst: eine individualpsychologische Analyse der Alzheimer Krankheit. Z Individualpsychol 24: 186–202Google Scholar
  33. Kropiunigg U, Sebek K, Leonhardsberger A, Schemper M, Dal-Bianco P (1999) Psychosoziale Risikofaktoren für die Alzheimer Krankheit. Psychother Psychosom Med Psychol 49: 153–159PubMedGoogle Scholar
  34. Lattmann UP, Wuchterl K (1992) Der Topos der Kompensation bei Alfred Adler — Anmerkungen aus der Sicht der philosophischen Anthropologie. Z Individualpsychol 17: 3–18Google Scholar
  35. Lewis D, Rodgers D, Woolcock M (2008) The fiction of development: literary representation as a source of authoritative knowledge. J Dev Studies 44: 198–216CrossRefGoogle Scholar
  36. Lunde A (2008) Lifestyle strategies may slow or prevent decline. Mayo Clinic medical information and tools for healthy living: http://www.mayoclinic.com/health/alzheimer/AZ99999Google Scholar
  37. McEwen BS (2008) Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 583: 174–185PubMedCrossRefGoogle Scholar
  38. McEwen BS (2000) Effects of adverse experiences for brain structure and function. Biol Psychiatry 48: 721–731PubMedCrossRefGoogle Scholar
  39. McLuhan M (1964) Understanding Media: The Extensions of Man. McGraw-Hill, New YorkGoogle Scholar
  40. Meaney MJ (2001) Nature, nurture, and the disunity of knowledge. Ann NY Acad Sci 935: 50–61PubMedCrossRefGoogle Scholar
  41. Miller DW (1995) The psychobiological nature of reality with a theory about Alzheimer’s. Advances 9: 69–76Google Scholar
  42. Roach M (1985) Another name for madness. Houghton and Mifflin, BostonGoogle Scholar
  43. Sapolsky RM (1996) Why stress in bad for your brain. Science 273: 749–750PubMedCrossRefGoogle Scholar
  44. Schroots JJF (1996) Theoretical developments in the psychology of aging. The Gerontologist 36: 742–749PubMedGoogle Scholar
  45. Shalat SL, Seltzer B, Pidcock C, Baker EL Jr (1987) Risk factors for Alzheimer’s disease: a case-control study. Neurology 37: 1630–1633PubMedGoogle Scholar
  46. Speck CE, Kukull WA, Brenner DE et al. (1995) History of depression as a risk factor for Alzheimer’s disease. Epidemiology 6: 366–369PubMedCrossRefGoogle Scholar
  47. Tomlinson BE, Blessed G, Roth M (1970) Observations on the brains of demented old people. J Neurol Sci 11: 205–242PubMedCrossRefGoogle Scholar
  48. von Uexküll T (2001) Körper-Seins, Körper-Haben — Der Hintergrund des Dualismus in der Medizin. Psychother Psychosom Med Psychol 51: 128–133CrossRefGoogle Scholar
  49. Wilson RS, Barnes LL, Mendes de Leon CF et al. (2002) Depressive symptoms cognitive dedine, and risk of AD in older persons. Neurology 59: 364–370PubMedGoogle Scholar
  50. Wittgenstein L (2003) Logisch-philosophische Abhandlung. Tractatus logico-philosophicus. Suhrkamp, Frankfurt am MainGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2009

Authors and Affiliations

  • Jerzy Leszek
    • 1
  • Andrzej Kiejna
    • 1
  • Ulrich Michael Hemmeter
    • 2
  • Ulrich Kropiunigg
    • 3
  1. 1.Department of PsychiatryWroclaw Medical UniversityWroclawPoland
  2. 2.Kantonale Psychiatrische Dienste St. GallenWil/SGSwitzerland
  3. 3.Institut für Medizinische Psychologie Zentrum für Public Health derMedizinischen Universität WienWienAustria

Personalised recommendations